SCHEMBL1484348

SCHEMBL1484348

O=C(O)c1ccc(NC(=S)NN=Cc2csc(-c3ccc(Cl)c(Cl)c3)c2O)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.43
MEN1 O00255 5/20 0.43
RAB9A P51151 5/20 0.43
NPC1 O15118 4/20 0.43
NPSR1 Q6W5P4 3/20 0.43
LMNA P02545 1/20 0.43
ALDH1A1 P00352 7/20 0.43
MAPT P10636 6/20 0.43
KDM4E B2RXH2 6/20 0.43
GAA P10253 4/20 0.43
L3MBTL1 Q9Y468 3/20 0.43
PKM P14618 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
POLB P06746 1/20 0.43
RECQL P46063 1/20 0.43
CTDSP1 Q9GZU7 1/20 0.43
SMN1; SMN2 Q16637 4/20 0.42
HDAC8 Q9BY41 2/20 0.40
HTT P42858 1/20 0.39
PHGDH O43175 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1484346 1.00 KMT2A (0.43) KMT2AMEN1RAB9ANPC1NPSR1
SCHEMBL1483414 0.86 SIRT1 (0.45) KMT2AMEN1RAB9ANPC1LMNA
SCHEMBL1483411 0.86 SIRT1 (0.45) KMT2AMEN1RAB9ANPC1LMNA
SCHEMBL1483333 0.83 EPHX2 (0.45) KMT2AMEN1RAB9ANPC1NPSR1
SCHEMBL1483330 0.83 EPHX2 (0.45) KMT2AMEN1RAB9ANPC1NPSR1
SCHEMBL1483041 0.80 KMT2A (0.39) KMT2AMEN1RAB9ANPC1NPSR1
SCHEMBL12829640 0.80 KMT2A (0.39) KMT2AMEN1RAB9ANPC1NPSR1
SCHEMBL1483045 0.80 KMT2A (0.39) KMT2AMEN1RAB9ANPC1NPSR1
SCHEMBL5357801 0.77 KDM4E (0.54) KMT2AMEN1RAB9ANPC1NPSR1
SCHEMBL5357804 0.77 KDM4E (0.54) KMT2AMEN1RAB9ANPC1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1636192-B9 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL IND LTD (JP) 2015-07-01 EP disclosed
US-20140051857-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES LIMITED (JP) 2014-02-20 US disclosed
EP-1636192-B1 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL IND LTD (JP) 2014-01-15 EP disclosed
US-20130012708-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES LIMITED (JP) 2013-01-10 US disclosed
US-8318796-B2 Heterocyclic compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-11-27 US disclosed
US-20110077290-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES LIMITED (JP) 2011-03-31 US disclosed
US-7576115-B2 Heterocyclic compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-08-18 US disclosed
US-7351841-B2 Heterocyclic compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2008-04-01 US disclosed
US-20080027068-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES LIMITED (JP) 2008-01-31 US disclosed
CN-1798739-A 3-alkylidenehydrazino substituted heteroaryl compounds as thrombopoietin receptor activators NISSAN CHEMICAL IND LTD (JP) 2006-07-05 CN disclosed
US-20060094694-A1 Heterocyclic compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES LIMITED (JP) 2006-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110077290-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NR2C2, ROR1, NR0B2 KMT2A 3762/4885MEN1 2583/4885RAB9A 3863/4885
US-20060094694-A1 Heterocyclic compounds and thrombopoietin receptor activators NR2C2, ROR1, NR0B2 KMT2A 3696/4885MEN1 2504/4885RAB9A 3796/4885
US-20080027068-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NR2C2, ROR1, NR0B2 KMT2A 3797/4885MEN1 2551/4885RAB9A 3877/4885
US-20140051857-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NR2C2, ROR1, NR0B2 KMT2A 3762/4885MEN1 2583/4885RAB9A 3863/4885
US-20130012708-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NR2C2, ROR1, NR0B2 KMT2A 3762/4885MEN1 2583/4885RAB9A 3863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.